{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T20:32:02Z","timestamp":1769805122150,"version":"3.49.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T00:00:00Z","timestamp":1764374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Astrazeneca"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12325-025-03420-3","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T11:43:50Z","timestamp":1764416630000},"page":"407-424","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment Pathway and Clinical Outcomes of the Population with Muscle-invasive Bladder Cancer in Italy: A Real-world Analysis with Administrative Databases"],"prefix":"10.1007","volume":"43","author":[{"given":"Paolo","family":"Luraghi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5018-490X","authenticated-orcid":false,"given":"Valentina","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Castelletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Losi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Risi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Mazzoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7020-6659","authenticated-orcid":false,"given":"Luca Degli","family":"Esposti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Antonuzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,29]]},"reference":[{"key":"3420_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"3420_CR2","doi-asserted-by":"publisher","first-page":"1170124","DOI":"10.3389\/fonc.2023.1170124","volume":"13","author":"K Grabe-Heyne","year":"2023","unstructured":"Grabe-Heyne K, Henne C, Mariappan P, Geiges G, P\u00f6hlmann J, Pollock RF. Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs. Front Oncol. 2023;13:1170124. https:\/\/doi.org\/10.3389\/fonc.2023.1170124.","journal-title":"Front Oncol"},{"key":"3420_CR3","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.2174\/1389557516666160512151202","volume":"20","author":"M Boegemann","year":"2020","unstructured":"Boegemann M, Krabbe L-M. Prognostic implications of immunohistochemical biomarkers in non-muscle-invasive blad cancer and muscle-invasive bladder cancer. MRMC. 2020;20:1133\u201352. https:\/\/doi.org\/10.2174\/1389557516666160512151202.","journal-title":"MRMC"},{"key":"3420_CR4","unstructured":"National Collaborating Centre for Cancer (UK). Bladder Cancer: Diagnosis and Management. London: National Institute for Health and Care Excellence (NICE); 2015 Feb. (NICE Guideline, No. 2.) 5, Managing muscle-invasive bladder cancer [Internet]. [cited 2025 Oct 22]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK356289. Accessed 22 Oct 2025"},{"key":"3420_CR5","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s12957-022-02664-5","volume":"20","author":"T Xu","year":"2022","unstructured":"Xu T, Gu W, Wang X, Xia L, He Y, Dong F, et al. Distant metastasis without regional progression in non-muscle invasive bladder cancer: case report and pooled analysis of literature. World J Surg Oncol. 2022;20:226. https:\/\/doi.org\/10.1186\/s12957-022-02664-5.","journal-title":"World J Surg Oncol"},{"key":"3420_CR6","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","volume":"71","author":"S Antoni","year":"2017","unstructured":"Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71:96\u2013108. https:\/\/doi.org\/10.1016\/j.eururo.2016.06.010.","journal-title":"Eur Urol"},{"key":"3420_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12050726","volume":"12","author":"MPA Starmans","year":"2022","unstructured":"Starmans MPA, Ho LS, Smits F, Beije N, De Kruijff I, De Jong JJ, et al. Optimization of preoperative lymph node staging in patients with muscle-invasive bladder cancer using radiomics on computed tomography. J Pers Med. 2022;12:726. https:\/\/doi.org\/10.3390\/jpm12050726.","journal-title":"J Pers Med"},{"key":"3420_CR8","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.21037\/tau.2020.03.23","volume":"9","author":"K Aminoltejari","year":"2020","unstructured":"Aminoltejari K, Black PC. Radical cystectomy: a review of techniques, developments and controversies. Transl Androl Urol. 2020;9:3073\u201381. https:\/\/doi.org\/10.21037\/tau.2020.03.23.","journal-title":"Transl Androl Urol"},{"key":"3420_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104557","volume":"205","author":"C Baudelin","year":"2025","unstructured":"Baudelin C, Sargos P, Dinart D, Hennequin C, Teyssonneau D, Meynard L, et al. Concomitant chemotherapy in trimodal treatment of patients with muscle invasive bladder cancer: a systematic review of prospective trials. Crit Rev Oncol Hematol. 2025;205:104557. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104557.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3420_CR10","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","volume":"24","author":"AR Zlotta","year":"2023","unstructured":"Zlotta AR, Ballas LK, Niemierko A, Lajkosz K, Kuk C, Miranda G, et al. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. Lancet Oncol. 2023;24:669\u201381. https:\/\/doi.org\/10.1016\/S1470-2045(23)00170-5.","journal-title":"Lancet Oncol"},{"key":"3420_CR11","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMoa022148","volume":"349","author":"HB Grossman","year":"2003","unstructured":"Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859\u201366. https:\/\/doi.org\/10.1056\/NEJMoa022148.","journal-title":"N Engl J Med"},{"key":"3420_CR12","unstructured":"AIOM (Italian Medical Oncology Association): Guidelines of Urothelial Tumours (ed. 2024). [Internet]. [cited 2025 Oct 23]. https:\/\/www.iss.it\/documents\/20126\/8403839\/LG_459_AIOM_Urotelio_agg2024.pdf. Accessed 23 Oct 2025"},{"key":"3420_CR13","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","volume":"33","author":"T Powles","year":"2022","unstructured":"Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, et al. Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:244\u201358. https:\/\/doi.org\/10.1016\/j.annonc.2021.11.012.","journal-title":"Ann Oncol"},{"key":"3420_CR14","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S1470-2045(10)70275-8","volume":"12","author":"MD Galsky","year":"2011","unstructured":"Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011;12:211\u20134. https:\/\/doi.org\/10.1016\/S1470-2045(10)70275-8.","journal-title":"Lancet Oncol"},{"key":"3420_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31\u201341. https:\/\/doi.org\/10.1159\/000180580.","journal-title":"Nephron"},{"key":"3420_CR16","unstructured":"Distribution of Body-Mass-Index (BMI) in Italy 2023, by age. [Internet]. [cited 2025 Oct 23]. https:\/\/www.statista.com\/statistics\/727866\/distribution-of-body-mass-index-by-age-italy\/. Accessed 23 Oct 2025"},{"key":"3420_CR17","doi-asserted-by":"publisher","first-page":"e1511","DOI":"10.1093\/oncolo\/oyae160","volume":"29","author":"R Pichler","year":"2024","unstructured":"Pichler R, Fritz J, Mari A, Cadenar A, Von Deimling M, Marcq G, et al. Cisplatin eligibility in the neoadjuvant setting of patients with muscle-invasive bladder cancer undergoing radical cystectomy. Oncologist. 2024;29:e1511\u201322. https:\/\/doi.org\/10.1093\/oncolo\/oyae160.","journal-title":"Oncologist"},{"key":"3420_CR18","doi-asserted-by":"crossref","unstructured":"Thompson RH, Boorjian SA, Kim SP, Cheville JC, Thapa P, Tarrel R, et al. Eligibility for neoadjuvant\/adjuvant cisplatin\u2010based chemotherapy among radical cystectomy patients. BJU International [Internet]. 2014 [cited 2025 Oct 23];113. https:\/\/doi.org\/10.1111\/bju.12274","DOI":"10.1111\/bju.12274"},{"key":"3420_CR19","unstructured":"Eastern Cooperative Oncology Group: ECOG Performance Status Scale. [Internet]. [cited 2025 Oct 23]. https:\/\/ecog-acrin.org\/resources\/ecog-performance-status\/. Accessed 23 Oct 2025"},{"key":"3420_CR20","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1001\/jamaoncol.2015.2378","volume":"1","author":"HG Prigerson","year":"2015","unstructured":"Prigerson HG, Bao Y, Shah MA, Paulk ME, LeBlanc TW, Schneider BJ, et al. Chemotherapy use, performance status, and quality of life at the end of life. JAMA Oncol. 2015;1:778\u201384. https:\/\/doi.org\/10.1001\/jamaoncol.2015.2378.","journal-title":"JAMA Oncol"},{"key":"3420_CR21","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.urology.2024.08.067","volume":"194","author":"S Kronstedt","year":"2024","unstructured":"Kronstedt S, Saffati G, Hinojosa-Gonzalez DE, Doppalapudi SK, Boyle J, Chua K, et al. Early adjuvant chemotherapy improves survival in muscle invasive bladder cancer: a systematic review and meta-analysis. Urology. 2024;194:289\u201394. https:\/\/doi.org\/10.1016\/j.urology.2024.08.067.","journal-title":"Urology"},{"key":"3420_CR22","unstructured":"Gruppo di Lavoro AIOM - AIRTUM - Fondazione AIOM. I numeri del cancro in Italia 2023. [Internet]. [cited 2025 Oct 23]. https:\/\/www.aiom.it\/wp-content\/uploads\/2024\/02\/2023_AIOM_NDC-web_def.pdf. Accessed 23 Oct 2025"},{"key":"3420_CR23","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3322\/caac.21631","volume":"70","author":"VG Patel","year":"2020","unstructured":"Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020;70:404\u201323. https:\/\/doi.org\/10.3322\/caac.21631.","journal-title":"CA Cancer J Clin"},{"key":"3420_CR24","doi-asserted-by":"crossref","unstructured":"De Nunzio C, Giannatempo P, Passalacqua R, Fiorini E, Luccarini I, Brigido A. Epidemiology and unmet needs of bladder cancer in Italy: a critical review. Minerva Urol Nefrol [Internet]. 2020 [cited 2025 Oct 23];72. https:\/\/doi.org\/10.23736\/S0393\u20132249.19.03498\u20132","DOI":"10.23736\/S0393-2249.19.03498-2"},{"key":"3420_CR25","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2147\/CEOR.S135065","volume":"9","author":"C Gerace","year":"2017","unstructured":"Gerace C, Montorsi F, Tambaro R, Carten\u00ec G, De Luca S, Tucci M, et al. Cost of illness of urothelial bladder cancer in Italy. CEOR. 2017;9:433\u201342. https:\/\/doi.org\/10.2147\/CEOR.S135065.","journal-title":"CEOR"},{"key":"3420_CR26","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8.","journal-title":"J Chronic Dis"},{"key":"3420_CR27","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1002\/ijc.28716","volume":"135","author":"CA Goossens-Laan","year":"2014","unstructured":"Goossens-Laan CA, Leliveld AM, Verhoeven RHA, Kil PJM, De Bock GH, Hulshof MCCM, et al. Effects of age and comorbidity on treatment and survival of patients with muscle-invasive bladder cancer. Intl J Cancer. 2014;135:905\u201312. https:\/\/doi.org\/10.1002\/ijc.28716.","journal-title":"Intl J Cancer"},{"key":"3420_CR28","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-2108","volume":"8","author":"Y Zang","year":"2020","unstructured":"Zang Y, Li X, Cheng Y, Qi F, Yang N. An overview of patients with urothelial bladder cancer over the past two decades: a Surveillance, Epidemiology, and End Results (SEER) study. Ann Transl Med. 2020;8:1587\u20131587. https:\/\/doi.org\/10.21037\/atm-20-2108.","journal-title":"Ann Transl Med"},{"key":"3420_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/medsci8010015","volume":"8","author":"K Saginala","year":"2020","unstructured":"Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of bladder cancer. Med Sci. 2020;8:15. https:\/\/doi.org\/10.3390\/medsci8010015.","journal-title":"Med Sci"},{"key":"3420_CR30","unstructured":"Cancer research UK - Bladder cancer incidence statistics [Internet]. [cited 2025 Oct 23]. https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/bladder-cancer\/incidence. Accessed 23 Oct 2025"},{"key":"3420_CR31","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1007\/s00345-023-04443-7","volume":"41","author":"LMC Van Hoogstraten","year":"2023","unstructured":"Van Hoogstraten LMC, Man CCO, Witjes JA, Meijer RP, Mulder SF, Smilde TJ, et al. Low adherence to recommended use of neoadjuvant chemotherapy for muscle-invasive bladder cancer. World J Urol. 2023;41:1837\u201345. https:\/\/doi.org\/10.1007\/s00345-023-04443-7.","journal-title":"World J Urol"},{"key":"3420_CR32","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1002\/cncr.25641","volume":"117","author":"T MacKenzie","year":"2011","unstructured":"MacKenzie T, Zens MS, Ferrara A, Schned A, Karagas MR. Diabetes and risk of bladder cancer: evidence from a case-control study in New England. Cancer. 2011;117:1552\u20136. https:\/\/doi.org\/10.1002\/cncr.25641.","journal-title":"Cancer"},{"key":"3420_CR33","doi-asserted-by":"publisher","first-page":"512","DOI":"10.3390\/jpm13030512","volume":"13","author":"B Barone","year":"2023","unstructured":"Barone B, Finati M, Cinelli F, Fanelli A, Del Giudice F, De Berardinis E, et al. Bladder cancer and risk factors: data from a multi-institutional long-term analysis on cardiovascular disease and cancer incidence. JPM. 2023;13:512. https:\/\/doi.org\/10.3390\/jpm13030512.","journal-title":"JPM"},{"key":"3420_CR34","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.eururo.2012.02.028","volume":"61","author":"RE Hautmann","year":"2012","unstructured":"Hautmann RE, De Petriconi RC, Pfeiffer C, Volkmer BG. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol. 2012;61:1039\u201347. https:\/\/doi.org\/10.1016\/j.eururo.2012.02.028.","journal-title":"Eur Urol"},{"key":"3420_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-72820-y","volume":"10","author":"DJ Reesink","year":"2020","unstructured":"Reesink DJ, Van De Garde EMW, Peters BasJM, Van Der Nat PB, Los M, Horenblas S, et al. Treatment patterns and clinical outcomes of chemotherapy treatment in patients with muscle-invasive or metastatic bladder cancer in the Netherlands. Sci Rep. 2020;10:15822. https:\/\/doi.org\/10.1038\/s41598-020-72820-y.","journal-title":"Sci Rep"},{"key":"3420_CR36","unstructured":"National Cancer Institute: Bladder Cancer Prognosis and Survival Rates [Internet]. [cited 2025 Oct 23]. https:\/\/www.cancer.gov\/types\/bladder\/survival?utm_source. Accessed 23 Oct 2025"},{"key":"3420_CR37","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1186\/s12885-021-08418-y","volume":"21","author":"J Ripoll","year":"2021","unstructured":"Ripoll J, Ramos M, Monta\u00f1o J, Pons J, Ameijide A, Franch P. Cancer-specific survival by stage of bladder cancer and factors collected by Mallorca Cancer Registry associated to survival. BMC Cancer. 2021;21:676. https:\/\/doi.org\/10.1186\/s12885-021-08418-y.","journal-title":"BMC Cancer"},{"key":"3420_CR38","unstructured":"Cancer research UK - Survival for bladder cancer. [Internet]. [cited 2025 Oct 23]. https:\/\/www.cancerresearchuk.org\/about-cancer\/bladder-cancer\/survival?utm_source. Accessed 23 Oct 2025"},{"key":"3420_CR39","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.euros.2022.02.010","volume":"39","author":"B-M De Ruiter","year":"2022","unstructured":"De Ruiter B-M, Van De Kamp MW, Van Steenbergen JPZ, Franckena M, Boormans JL, De Feijter JM, et al. A multicenter retrospective cohort series of muscle-invasive bladder cancer patients treated with definitive concurrent chemoradiotherapy in daily practice. European Urology Open Science. 2022;39:7\u201313. https:\/\/doi.org\/10.1016\/j.euros.2022.02.010.","journal-title":"European Urology Open Science"},{"key":"3420_CR40","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","volume":"391","author":"T Powles","year":"2024","unstructured":"Powles T, Catto JWF, Galsky MD, Al-Ahmadie H, Meeks JJ, Nishiyama H, et al. Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. N Engl J Med. 2024;391:1773\u201386. https:\/\/doi.org\/10.1056\/NEJMoa2408154.","journal-title":"N Engl J Med"},{"key":"3420_CR41","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1080\/14737140.2025.2535657","volume":"25","author":"T Lee","year":"2025","unstructured":"Lee T, MacDonald L, Lawen T, Kamat AM. Optimizing cystectomy outcomes in muscle-invasive bladder cancer: what\u2019s new in 2025? Expert Rev Anticancer Ther. 2025;25:1181\u201393. https:\/\/doi.org\/10.1080\/14737140.2025.2535657.","journal-title":"Expert Rev Anticancer Ther"},{"key":"3420_CR42","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.euros.2022.02.011","volume":"39","author":"NC Grossmann","year":"2022","unstructured":"Grossmann NC, Rajwa P, Quhal F, K\u00f6nig F, Mostafaei H, Laukhtina E, et al. Comparative outcomes of primary versus recurrent high-risk non\u2013muscle-invasive and primary versus secondary muscle-invasive bladder cancer after radical cystectomy: results from a retrospective multicenter study. Eur Urol Open Sci. 2022;39:14\u201321. https:\/\/doi.org\/10.1016\/j.euros.2022.02.011.","journal-title":"Eur Urol Open Sci"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03420-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03420-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03420-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T09:32:06Z","timestamp":1769765526000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03420-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,29]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["3420"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03420-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,29]]},"assertion":[{"value":"17 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Paolo Luraghi, Daniela Castelletti, Serena Losi, and Matteo Risi are employees of AstraZeneca. Lorenzo Antonuzzo received payment or honoraria for lectures and presentations from AstraZeneca, Roche, Astellas, Novartis, MSD, BMS, Ipsen, Merck Serono, Amgen, and Bayer; support for attending meetings and\/or travel grants from AstraZeneca, Novartis, Ipsen, and Merck Serono; and research funding to his institution from Novartis and AstraZeneca. Valentina Perrone, Stefania Mazzoni, and Luca Degli Esposti have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Approval has been obtained from the following ethics committees of the involved local healthcare entities: authorization of the Ethics Committee \u201cBAT (Barletta-Andria-Trani) Comitato etico interprovinciale Area I\u201d (protocol no. 68\/CE\/20, approval date 3\/12\/2020); authorization of the Ethics Committee of Bergamo (protocol no. 330, approval date 6\/4\/2023); authorization of the Ethics Committee \u201cBerica Comitato Etico per le Sperimentazioni Cliniche (CESC) della Provincia di Vicenza\u201d (protocol no. 1627, approval date 28\/10\/2020); authorization of the Ethics Committee \u201cFoggia Comitato etico interprovinciale Area I\u201d (protocol no. 63\/CE\/20, approval date 3\/12\/2020); authorization of the Ethics Committee \u201cFrosinone Comitato Etico Lazio 2\u201d (protocol no. 0179046\/2020, approval date 28\/10\/2020); authorization of the Ethics Committee \u201cRoma 3 Comitato Etico Lazio 2\u201d (protocol no. 0031200\/2021, approval date 10\/02\/2021); authorization of the Ethics Committee \u201cRoma 6 Comitato Etico Lazio 2\u201d (protocol no. 0216084\/2020, approval date 16\/12\/2020); authorization of the Ethics Committee \u201cSerenissima Comitato Etico per la Sperimentazione Clinica della provincia di Venezia e IRCCS S. Camillo\u201d (28\/07\/2020); authorization of the Ethics Committee \u201cUmbria 2 Comitato Etico Regionale Umbria\u201d (protocol no. 19414\/20\/ON, approval date 16\/09\/2020); authorization of the Ethics Committee \u201cVercelli Comitato Etico Interaziendale A.O. SS. Antonio e Biagio e Cesare Arrigo \u2013 Alessandria\u201d (protocol no. 0008668, approval date 20\/04\/2021).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}